Aastrom Biosciences Receives Patent Expanding Coverage for its Single-pass Perfusion Technology
Patent Extends Coverage from Stem Cell Population to Dendritic Cells
Advertisement
Aastrom Biosciences, Inc. announced that it has received a patent providing expanded coverage for the Company's single-pass perfusion technology to cover enhancing the biological functionality of human dendritic cells produced in cell culture. Dendritic cells are in clinical trials and experimental evaluations as vaccines for numerous forms of cancer and infectious diseases at various academic institutions and companies.
Aastrom is currently engaged in on-going clinical trial collaborations at Stanford University evaluating dendritic cells produced with this technology.